PATRICK DEVAL L - 05 Oct 2022 Form 4 Insider Report for Global Blood Therapeutics, Inc.

Role: Director
Signature: /s/ Miguel Carrillo, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 05 Oct 2022
Net transactions value: $0
Form type: 4
Filing time: 06 Oct 2022, 16:20:58 UTC
Previous filing: 19 Sep 2022
Next filing: 19 Dec 2022
SEC: View on sec.gov

Key filing fact

PATRICK DEVAL L filed Form 4 for Global Blood Therapeutics, Inc. on 06 Oct 2022.

Key facts

This page summarizes PATRICK DEVAL L's Form 4 filing for Global Blood Therapeutics, Inc..
6 reported transactions and 5 derivative rows are listed below.
Filing timestamp: 06 Oct 2022, 16:20.

Change

Previous filing in this sequence was filed on 19 Sep 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Transactions Table

GBT transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -9,037
Change %: -100%
Price
Shares after: 0
Date: 05 Oct 2022
Ownership: Direct
Footnotes: F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

GBT transaction Derivative

Restricted Stock Units

Disposed to Issuer

Transaction value
Shares: -3,600
Change %: -100%
Price
Shares after: 0
Date: 05 Oct 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,600
Exercise price
Footnotes: F3, F4

GBT transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -625
Change %: -100%
Price
Shares after: 0
Date: 05 Oct 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 625
Exercise price: $68.75
Footnotes: F5

GBT transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -5,247
Change %: -100%
Price
Shares after: 0
Date: 05 Oct 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,247
Exercise price: $64.75
Footnotes: F5

GBT transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -5,600
Change %: -100%
Price
Shares after: 0
Date: 05 Oct 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,600
Exercise price: $37.09
Footnotes: F5

GBT transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -5,600
Change %: -100%
Price
Shares after: 0
Date: 05 Oct 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,600
Exercise price: $22.30
Footnotes: F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

PATRICK DEVAL L is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement.
F2	(Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.
F3	Each restricted stock unit of the Issuer ("RSU") represented a contingent right to receive one share of Common Stock.
F4	Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.
F5	Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Any Issuer Stock Option with an exercise price per share that is greater than or equal to the Merger Consideration was canceled at the Effective Time for no consideration or payment.